Literature DB >> 16450384

Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo.

Jérôme Alexandre1, Frédéric Batteux, Carole Nicco, Christiane Chéreau, Alexis Laurent, Loïc Guillevin, Bernard Weill, François Goldwasser.   

Abstract

Intracellular events following paclitaxel binding to microtubules that lead to cell death remain poorly understood. Because reactive oxygen species (ROS) are involved in the cytotoxicity of anticancer agents acting through independent molecular targets, we explored the role of ROS in paclitaxel cytotoxicity. Within 15 min after in vitro exposure of A549 human lung cancer cells to paclitaxel, a concentration-dependent intracellular increase in O(o)(2)(-) and H(2)O(2) levels was detected by spectrofluorometry. Addition of N-acetylcysteine (NAC) or glutathione, two H(2)O(2) scavenger, induced a 4-fold increase in paclitaxel IC(50). Delaying NAC co-incubation by 4 hr, resulted in a 3-fold reduction in cell protection. The glutathione synthesis inhibitor, buthionine sulfoximine significantly increased paclitaxel cytotoxicity and H(2)O(2) accumulation, but did not modify O(o)(2)(-) levels. Co-incubation with diphenylene iodonium suggested that paclitaxel induced-O(o)(2)(-) production was in part associated with increased activity of cytoplasmic NADPH oxidase. Concomitant treatment with inhibitors of caspases 3 and 8 increased cell survival but did not prevent the early accumulation of H(2)O(2.) To evaluate the role of ROS in paclitaxel antitumoral activity, mice were injected with LLC1 lung cancer cells and treated with paclitaxel i.p. and/or NAC. The antitumoral activity of paclitaxel in mice was abolished by NAC. In conclusion, the accumulation of H(2)O(2) is an early and crucial step for paclitaxel-induced cancer cell death before the commitment of the cells into apoptosis. These results suggest that ROS participate in vitro and in vivo to paclitaxel cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16450384     DOI: 10.1002/ijc.21685

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  89 in total

Review 1.  The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells.

Authors:  Lianqin Li; Ai-Qun Yu
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-21       Impact factor: 4.553

Review 2.  Cellular redox pathways as a therapeutic target in the treatment of cancer.

Authors:  Alberto J Montero; Jacek Jassem
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

3.  Alpha-tocopheryl succinate potentiates the paclitaxel-induced apoptosis through enforced caspase 8 activation in human H460 lung cancer cells.

Authors:  Soo-Jeong Lim; Moon Kyung Choi; Min Jung Kim; Joo Kyoung Kim
Journal:  Exp Mol Med       Date:  2009-10-31       Impact factor: 8.718

Review 4.  Glucose deprivation-induced metabolic oxidative stress and cancer therapy.

Authors:  Andrean L Simons; David M Mattson; Ken Dornfeld; Douglas R Spitz
Journal:  J Cancer Res Ther       Date:  2009-09       Impact factor: 1.805

5.  Phenethyl isothiocyanate induces cell cycle arrest and reduction of alpha- and beta-tubulin isotypes in human prostate cancer cells.

Authors:  Ping Yin; Tomoya Kawamura; Meilan He; Donkena Krishna Vanaja; Charles Y F Young
Journal:  Cell Biol Int       Date:  2008-10-11       Impact factor: 3.612

6.  Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress.

Authors:  Tanja Hadzic; Nükhet Aykin-Burns; Yueming Zhu; Mitchell C Coleman; Katie Leick; Geraldine M Jacobson; Douglas R Spitz
Journal:  Free Radic Biol Med       Date:  2010-01-18       Impact factor: 7.376

7.  NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance.

Authors:  Francesco Marampon; Silvia Codenotti; Francesca Megiorni; Andrea Del Fattore; Simona Camero; Giovanni Luca Gravina; Claudio Festuccia; Daniela Musio; Francesca De Felice; Valerio Nardone; Anna Natalizia Santoro; Carlo Dominici; Alessandro Fanzani; Luigi Pirtoli; Antonella Fioravanti; Vincenzo Tombolini; Sara Cheleschi; Paolo Tini
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-30       Impact factor: 4.553

8.  ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage.

Authors:  Xiaohua Peng; Varsha Gandhi
Journal:  Ther Deliv       Date:  2012-07

Review 9.  Redox regulation in cancer: a double-edged sword with therapeutic potential.

Authors:  Asha Acharya; Ila Das; Des Chandhok; Tapas Saha
Journal:  Oxid Med Cell Longev       Date:  2010 Jan-Feb       Impact factor: 6.543

10.  4-oxo-N-(4-hydroxyphenyl)retinamide: two independent ways to kill cancer cells.

Authors:  Paola Tiberio; Elena Cavadini; Gabriella Abolafio; Franca Formelli; Valentina Appierto
Journal:  PLoS One       Date:  2010-10-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.